You are here: Industry Insights > CytoDyn

News List

CytoDyn Appoints Seenu Srinivasan as Executive Director of CMC Regulatory Affairs firstwordpharma
August 27, 2021
CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company") announced today the appointment of Seenu Srinivasan, Ph.D., as Executive Director-CMC Regulatory Affairs.
Monoclonal antibody prevents HIV infection in monkeys, study finds worldpharmanews
June 10, 2021
An experimental, lab-made antibody can completely prevent nonhuman primates from being infected with the monkey form of HIV, new research published in Nature Communications shows.
CytoDyn to seek regulatory approval for Covid-19 drug Vyrologix pharmaceutical-technology
May 20, 2021
CytoDyn is set to submit the results from the Phase III CD12 clinical trial of Vyrologix (leronlimab-PRO 140), seeking potential regulatory approval for the drug to treat severe to critically ill patients with Covid-19.
CytoDyn and Biomm enter leronlimab supply agreement pharmaceutical-technology
April 09, 2021
CytoDyn (CYDY) and Biomm have signed an exclusive supply and distribution agreement that will enable the latter to market CCR5 antagonist leronlimab (PRO 140) in Brazil on receiving regulatory approval.
Ajinomoto Bio-Pharma Services announces manufacturing partnership with CytoDyn for drug product used expresspharma
May 06, 2020
The company provides high-quality drug product aseptic fill finish services for CytoDyn.
Vyera licences HIV treatment from CytoDyn pharmaceutical-technology
December 23, 2019
Vyera Pharmaceuticals has entered agreements with CytoDyn to commercialise human immunodeficiency viruses (HIV) treatment leronlimab (PRO 140) in the US.
CytoDyn Evaluates Leronlimab for Triple-Negative Breast Cancer contractpharma
June 12, 2019
FDA grants CytoDyn Fast Tract Designation to evaluate leronlimab in combination with carboplatin for the treatment of triple-negative breast cancer.